ArticleTargeted oncology2020

Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.

Diana Lüftner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.